EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This study is currently recruiting participants.
Verified May 2013 by Gynecologic Oncology Group
Sponsor:
Gynecologic Oncology Group
Collaborators:
EGEN, Inc.
Information provided by (Responsible Party):
Gynecologic Oncology Group
ClinicalTrials.gov Identifier:
NCT01489371
First received: December 8, 2011
Last updated: May 6, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |